Hypertonic saline inhalation in cystic fibrosis - Salt in the wound, or sweet success?

Archives of Disease in Childhood

Volumn 92, Issue 3, 2007, Pages 195-196

  Enderby, Beth ^a   Doull, Iolo ^a  

^a CARDIFF AND VALE UNIVERSITY HEALTH BOARD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; COLISTIN; DENUFOSOL; DORNASE ALFA; MANNITOL; PLACEBO; SALBUTAMOL; SODIUM CHLORIDE; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

CHEST TIGHTNESS; CLINICAL TRIAL; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG COST; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MEDICAL PRACTICE; OPTIMAL DRUG DOSE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SCORING SYSTEM; SHORT SURVEY; SURVIVAL; TREATMENT OUTCOME; WOUND;

ADMINISTRATION, INHALATION; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; SALINE SOLUTION, HYPERTONIC; TREATMENT OUTCOME;

EID: 33947226347     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2006.094979     Document Type: Short Survey

References (26)

1. Hafen GM, Ranganathan SC, Robertson CF, et al. Clinical scoring systems in cystic fibrosis. Pediatr Pulmonol 2006;41:602- 17.
2. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:1187-91.
3. Cooper PJ, Robertson CF, Hudson IL, et al. Variability of pulmonary function tests in cystic fibrosis. Pediatr Pulmonol 1990;8:16-22.
4. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-42.
5. Rosenfeld M, Emerson J, Williams-Warren J, et al. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139:359-65.
6. Eng PA, Morton J, Douglass JA, et al. Robertson CF Short-term efficacy of ultrasonically nebulized hypertonic saline in cystic fibrosis. Pediatr Pulmonol 1996;21:77-83.
7. Rabin HR, Butler SM, Wohl MEB, et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004;37:400- 406.
8. Robinson M, Regnis JA, Bailey DL, et al. Effect of hypertonic saline, amiloride, and cough on mucociliary clearance in patients with cystic fibrosis. Am J Respir Crit Care Med 1996;153:1503-9.
9. Robinson M, Hemming AL, Regnis JA, et al. Effect of increasing doses of hypertonic saline on mucociliary clearance in patients with cystic fibrosis. Thorax 1997;52:900-3.
10. Suri R, Metcalfe C, Lees B, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001;358:1316-21.
11. Elkins MR, Robinson M, Rose BR, et al; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40.
12. Donaldson SH, Bennett WD, Zeman KL, et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006;354:241-50.
13. Daviskas E, Anderson SD, Gonda I, et al. Inhalation of hypertonic saline aerosol enhances mucociliary clearance in asthmatic and healthy subjects. Eur Respir J 1996;9:725-32.
14. Wark PA, McDonald V, Jones AP. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2005;20:CD001506.
15. Quan JM, Tiddens HA, Sy JP, et al; Pulmozyme Early Intervention Trial Study Group. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001;139:813-20.
16. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30.
17. Moss RB. Long term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002;121:55-63.
18. Wolter J, Seeney S, Bell S, et al. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002;57:212-16.
19. Saiman L, Marshall BC, Mayer-Hamblett N, et al; Macrolide Study Group. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290:1749-56.
20. Clement A, Tamalet A, Le Roux E, et al. Long term effects of azithromycin in patients with cystic fibrosis: a double-blind, placebo-controlled trial. Thorax 2006;61:895-902.
21. Ballmann M, von der Hardt H. Hypertonic saline and recombinant DNase: a randomised cross-over pilot study in patients with cystic fibrosis. J Cyst Fibrosis 2002;1:35-37.
22. Pauwels RA, Lofdahl CG, Postma DS, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997;337:1405-11.
23. Saiman L, Mayer-Hamblett N, Campbell P, et al; Macrolide Study Group Heterogeneity of treatment response to azithromycin in patients with cystic fibrosis. Am J Respir Crit Care Med 2005;172:1008-12.
24. Deterding R, Retsch-Bogart G, Milgram L, et al. Cystic Fibrosis Foundation Therapeutics Development Network. Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis, Pediatr Pulmonol 2005;39:339-48.
25. Wills P, Greenstone M. Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2006;2:CD002996.
26. Charlton B, Lassig A. Inhaled dry powder mannitol (bronchitol) improves FEV1 in cystic fibrosis. J Cyst Fibrosis 2006;5(Suppl 1):S11.